Document Detail


Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.
MedLine Citation:
PMID:  23153319     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Background: Patients treated with epidermal growth factor receptor inhibitors (EGFRIs) may develop dermatologic adverse drug reactions (ADRs) that may affect patients' quality of life, require medical care, and may lead to substantial costs. This study assessed the economic burden of dermatologic ADRs in colorectal cancer (CRC), head and neck cancer (HNC), and non-small cell lung cancer (NSCLC) patients. Methods: Adult patients with ≥ 1 diagnosis for the study cancer initiated on EGFRIs indicated for CRC, HNC, and NSCLC were selected from a large commercial database (MarketScan Commercial Database [2000-2010]*). For each cancer type, patients were classified into two mutually exclusive cohorts: "ADR" (patients with ≥ 1 ADR following EGFRI initiation) and "ADR-free" (patients without any ADR). Patients were observed from the index date up to the end of continuous healthcare plan enrollment or 90 days after EGFRI discontinuation, whichever occurred first. For each cancer group, the proportion of patients and the incidence rate (IR) of experiencing ≥1 dermatologic ADR were reported. Incidence rate ratios for healthcare resource utilization and monthly incremental costs (2010 USD) were estimated using Poisson regression and generalized linear or two-part models, respectively. Results: Overall, the proportion of patients with ≥1 ADR ranged between 20.5% and 36.4% across cancer groups (IR ranged between 44.2 and 57.4 per 100 patient-years). After adjusting for confounders, in each cancer group, ADR patients had higher incidence of healthcare resource utilization, generally driven by higher incidence of emergency room visits and incurred incremental total monthly healthcare costs that ranged between $2,284 and $3,210 across cancer groups. Limitations: There was no clinical measure of cancer staging and ADR severity in the database. Conclusions: Results suggest that patients with CRC, NSCLC, and HNC, who may benefit from EGFRI therapies, may also incur a substantial economic burden that is associated with dermatologic ADRs.
Authors:
Saurabh Ray; Vijayveer Bonthapally; Kyle D Holen; Geneviève Gauthier; Eric Q Wu; Martin Cloutier; Annie Guérin
Related Documents :
22961779 - Aberrant methylation of rasgrf1 is associated with an epigenetic field defect and incre...
24036439 - Feasibility and acceptability of the patient-reported outcomes measurement information ...
24280569 - Human equilibrative nucleoside transporter 1 (hent1): do we really have a new predictiv...
23426449 - Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer.
23497839 - The evolution of fear of cancer recurrence during the cancer care trajectory and its re...
23141849 - Three-month mortality rate and clinical predictors in patients with venous thromboembol...
9093139 - Transabdominal and transvaginal ultrasound detection of levonorgestrel iud in the uterus.
18514949 - American college of radiology appropriateness criteria on conservative surgery and radi...
19882039 - Cutaneous pancreatic metastasis: a case report and review of literature.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-16
Journal Detail:
Title:  Journal of medical economics     Volume:  -     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal...
Next Document:  'A chronic disease is a disease which keeps coming back…it is like the flu': chronic disease risk ...